Research ExplorerPublicationsShort- and long-term T cell and antibody responses following...

Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19

Standard

Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. / Thibeault, Charlotte; Bardtke, Lara; Vanshylla, Kanika; di Cristanziano, Veronica; Eberhardt, Kirsten A; Stubbemann, Paula; Hillus, David; Tober-Lau, Pinkus; Mukherjee, Parnika; Münn, Friederike; Lippert, Lena J; Helbig, Elisa T; Lingscheid, Tilman; Steinbeis, Fridolin; Mittermaier, Mirja; Witzenrath, Martin; Zoller, Thomas; Pa-COVID Study Group; Klein, Florian; Sander, Leif E; Kurth, Florian.

In: JCI INSIGHT, Vol. 8, No. 8, e166711, 24.04.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Thibeault, C, Bardtke, L, Vanshylla, K, di Cristanziano, V, Eberhardt, KA, Stubbemann, P, Hillus, D, Tober-Lau, P, Mukherjee, P, Münn, F, Lippert, LJ, Helbig, ET, Lingscheid, T, Steinbeis, F, Mittermaier, M, Witzenrath, M, Zoller, T, Pa-COVID Study Group, Klein, F, Sander, LE & Kurth, F 2023, 'Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19', JCI INSIGHT, vol. 8, no. 8, e166711. https://doi.org/10.1172/jci.insight.166711

APA

Thibeault, C., Bardtke, L., Vanshylla, K., di Cristanziano, V., Eberhardt, K. A., Stubbemann, P., Hillus, D., Tober-Lau, P., Mukherjee, P., Münn, F., Lippert, L. J., Helbig, E. T., Lingscheid, T., Steinbeis, F., Mittermaier, M., Witzenrath, M., Zoller, T., Pa-COVID Study Group, Klein, F., ... Kurth, F. (2023). Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. JCI INSIGHT, 8(8), [e166711]. https://doi.org/10.1172/jci.insight.166711

Vancouver

Thibeault C, Bardtke L, Vanshylla K, di Cristanziano V, Eberhardt KA, Stubbemann P et al. Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. JCI INSIGHT. 2023 Apr 24;8(8). e166711. https://doi.org/10.1172/jci.insight.166711

Bibtex

@article{4a51f18132b9421c825f66dc8853b07f,
title = "Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19",
abstract = "BACKGROUNDAfter its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce.METHODSWe included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charit{\'e}-Universit{\"a}tsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike-reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization.RESULTSPatients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence.CONCLUSIONDexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization.FUNDINGBerlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices.",
keywords = "Humans, Antibody Formation, SARS-CoV-2, COVID-19, COVID-19 Drug Treatment, T-Lymphocytes, Immunization, Secondary, Dexamethasone/therapeutic use",
author = "Charlotte Thibeault and Lara Bardtke and Kanika Vanshylla and {di Cristanziano}, Veronica and Eberhardt, {Kirsten A} and Paula Stubbemann and David Hillus and Pinkus Tober-Lau and Parnika Mukherjee and Friederike M{\"u}nn and Lippert, {Lena J} and Helbig, {Elisa T} and Tilman Lingscheid and Fridolin Steinbeis and Mirja Mittermaier and Martin Witzenrath and Thomas Zoller and {Pa-COVID Study Group} and Florian Klein and Sander, {Leif E} and Florian Kurth",
year = "2023",
month = apr,
day = "24",
doi = "10.1172/jci.insight.166711",
language = "English",
volume = "8",
journal = "JCI INSIGHT",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

RIS

TY - JOUR

T1 - Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19

AU - Thibeault, Charlotte

AU - Bardtke, Lara

AU - Vanshylla, Kanika

AU - di Cristanziano, Veronica

AU - Eberhardt, Kirsten A

AU - Stubbemann, Paula

AU - Hillus, David

AU - Tober-Lau, Pinkus

AU - Mukherjee, Parnika

AU - Münn, Friederike

AU - Lippert, Lena J

AU - Helbig, Elisa T

AU - Lingscheid, Tilman

AU - Steinbeis, Fridolin

AU - Mittermaier, Mirja

AU - Witzenrath, Martin

AU - Zoller, Thomas

AU - Pa-COVID Study Group

AU - Klein, Florian

AU - Sander, Leif E

AU - Kurth, Florian

PY - 2023/4/24

Y1 - 2023/4/24

N2 - BACKGROUNDAfter its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce.METHODSWe included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charité-Universitätsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike-reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization.RESULTSPatients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence.CONCLUSIONDexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization.FUNDINGBerlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices.

AB - BACKGROUNDAfter its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce.METHODSWe included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charité-Universitätsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike-reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization.RESULTSPatients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence.CONCLUSIONDexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization.FUNDINGBerlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices.

KW - Humans

KW - Antibody Formation

KW - SARS-CoV-2

KW - COVID-19

KW - COVID-19 Drug Treatment

KW - T-Lymphocytes

KW - Immunization, Secondary

KW - Dexamethasone/therapeutic use

U2 - 10.1172/jci.insight.166711

DO - 10.1172/jci.insight.166711

M3 - SCORING: Journal article

C2 - 36881474

VL - 8

JO - JCI INSIGHT

JF - JCI INSIGHT

SN - 2379-3708

IS - 8

M1 - e166711

ER -